Global Biologics and Biosimilars

Biologics and Biosimilars Comprehensive Study by Type (Monoclonal Antibodies, Interferon, Erythropoietin, Insulin, Vaccines, Other), Application (Tumor, Diabetes, Cardiovascular, Hemophilia, Other), Disease Type (Oncology, Blood Disorders, Chronic Diseases, Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Diseases), Route of administration (Injection, Infusion) Players and Region - Global Market Outlook to 2027

Biologics and Biosimilars Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Biologics and Biosimilars Market Overview:
Biologics and biosimilar are produced in living cells in a multi-step process that is unique for every manufacturer. By comparison, biologics are very large and have complex molecular structures, they are produced by using complex biotechnology process. It is difficult to produce the same copy of drugs without using the exact same ingredients, the same living cell lines, and identical manufacturing conditions. Once a patent expires for biologic it is legal for others manufactures to produce the drug, and these drugs are known as a biosimilar. Biosimilar is products that are similar to an already existing brand-name, original biologic, they are not identical to biologics they are just the replica of biologics.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Key Companies ProfiledRoche (Switzerland), Amgen (United States), AbbVie (United States), Sanofi-Aventis (France), Johnson & Johnson (United States), Pfizer (United States), Novo Nordisk (Denmark), Eli Lilly (United States), Novartis (United States) and Merck (United States)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Growth Drivers
  • Growing Number of the Aging Population Globally
  • Increasing Chronic and Infectious Diseases such as Kidney Diseases, Cancer and Autoimmune Diseases

Roadblocks
  • Lack of Automatic Substitution at the Pharmacy
  • High Manufacturing Concerns for Biologics


Challenges
  • Issues Related to the Complexity of Drug Molecules Structures for Biologics
  • Lack of Trained Healthcare Professionals and Stringent Approval Policies


Competitive Landscape:

Some of the key players profiled in the report are Roche (Switzerland), Amgen (United States), AbbVie (United States), Sanofi-Aventis (France), Johnson & Johnson (United States), Pfizer (United States), Novo Nordisk (Denmark), Eli Lilly (United States), Novartis (United States) and Merck (United States). Additionally, following companies can also be profiled that are part of our coverage like 3sbio (China), Changchun High Tech (China) and Ganlee (China). Analyst at AMA Research see Global Players to retain maximum share of Global Biologics and Biosimilars market by 2027. Considering Market by Disease Type, the sub-segment i.e. Oncology will boost the Biologics and Biosimilars market. Considering Market by Route of administration, the sub-segment i.e. Injection will boost the Biologics and Biosimilars market.



In 2018, FDA Commissioner Gottlieb introduced the Biosimilars Action Plan to help spur competition and innovation for biosimilars. As of March 2019, 18 biosimilars have been approved in the United States

What Can be Explored with the Biologics and Biosimilars Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Biologics and Biosimilars Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Biologics and Biosimilars
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Biologics and Biosimilars market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Biologics and Biosimilars market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Biologics and biosimilar Manufacturers, Health care Centers, Government and Research Organizations, Associations and Industrial Bodies, Research and Consulting Firms and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Interferon
  • Erythropoietin
  • Insulin
  • Vaccines
  • Other
By Application
  • Tumor
  • Diabetes
  • Cardiovascular
  • Hemophilia
  • Other
By Disease Type
  • Oncology
  • Blood Disorders
  • Chronic Diseases
  • Autoimmune Diseases
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Diseases

By Route of administration
  • Injection
  • Infusion

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of the Aging Population Globally
      • 3.2.2. Increasing Chronic and Infectious Diseases such as Kidney Diseases, Cancer and Autoimmune Diseases
    • 3.3. Market Challenges
      • 3.3.1. Issues Related to the Complexity of Drug Molecules Structures for Biologics
      • 3.3.2. Lack of Trained Healthcare Professionals and Stringent Approval Policies
    • 3.4. Market Trends
      • 3.4.1. The Increasing Rate of Patients and Physicians Willingness to Switch to Biosimilar
      • 3.4.2. Rising Approval of Biosimilar by FDA in the Forecasted year
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biologics and Biosimilars, by Type, Application, Disease Type, Route of administration and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Biologics and Biosimilars (Value)
      • 5.2.1. Global Biologics and Biosimilars by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Interferon
        • 5.2.1.3. Erythropoietin
        • 5.2.1.4. Insulin
        • 5.2.1.5. Vaccines
        • 5.2.1.6. Other
      • 5.2.2. Global Biologics and Biosimilars by: Application (Value)
        • 5.2.2.1. Tumor
        • 5.2.2.2. Diabetes
        • 5.2.2.3. Cardiovascular
        • 5.2.2.4. Hemophilia
        • 5.2.2.5. Other
      • 5.2.3. Global Biologics and Biosimilars by: Disease Type (Value)
        • 5.2.3.1. Oncology
        • 5.2.3.2. Blood Disorders
        • 5.2.3.3. Chronic Diseases
        • 5.2.3.4. Autoimmune Diseases
        • 5.2.3.5. Growth Hormone Deficiency
        • 5.2.3.6. Infectious Diseases
        • 5.2.3.7. Other Diseases
      • 5.2.4. Global Biologics and Biosimilars by: Route of administration (Value)
        • 5.2.4.1. Injection
        • 5.2.4.2. Infusion
      • 5.2.5. Global Biologics and Biosimilars Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Biologics and Biosimilars (Volume)
      • 5.3.1. Global Biologics and Biosimilars by: Type (Volume)
        • 5.3.1.1. Monoclonal Antibodies
        • 5.3.1.2. Interferon
        • 5.3.1.3. Erythropoietin
        • 5.3.1.4. Insulin
        • 5.3.1.5. Vaccines
        • 5.3.1.6. Other
      • 5.3.2. Global Biologics and Biosimilars by: Application (Volume)
        • 5.3.2.1. Tumor
        • 5.3.2.2. Diabetes
        • 5.3.2.3. Cardiovascular
        • 5.3.2.4. Hemophilia
        • 5.3.2.5. Other
      • 5.3.3. Global Biologics and Biosimilars by: Disease Type (Volume)
        • 5.3.3.1. Oncology
        • 5.3.3.2. Blood Disorders
        • 5.3.3.3. Chronic Diseases
        • 5.3.3.4. Autoimmune Diseases
        • 5.3.3.5. Growth Hormone Deficiency
        • 5.3.3.6. Infectious Diseases
        • 5.3.3.7. Other Diseases
      • 5.3.4. Global Biologics and Biosimilars by: Route of administration (Volume)
        • 5.3.4.1. Injection
        • 5.3.4.2. Infusion
      • 5.3.5. Global Biologics and Biosimilars Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Biologics and Biosimilars (Price)
      • 5.4.1. Global Biologics and Biosimilars by: Type (Price)
  • 6. Biologics and Biosimilars: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi-Aventis (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novo Nordisk (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Biologics and Biosimilars Sale, by Type, Application, Disease Type, Route of administration and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Biologics and Biosimilars (Value)
      • 7.2.1. Global Biologics and Biosimilars by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Interferon
        • 7.2.1.3. Erythropoietin
        • 7.2.1.4. Insulin
        • 7.2.1.5. Vaccines
        • 7.2.1.6. Other
      • 7.2.2. Global Biologics and Biosimilars by: Application (Value)
        • 7.2.2.1. Tumor
        • 7.2.2.2. Diabetes
        • 7.2.2.3. Cardiovascular
        • 7.2.2.4. Hemophilia
        • 7.2.2.5. Other
      • 7.2.3. Global Biologics and Biosimilars by: Disease Type (Value)
        • 7.2.3.1. Oncology
        • 7.2.3.2. Blood Disorders
        • 7.2.3.3. Chronic Diseases
        • 7.2.3.4. Autoimmune Diseases
        • 7.2.3.5. Growth Hormone Deficiency
        • 7.2.3.6. Infectious Diseases
        • 7.2.3.7. Other Diseases
      • 7.2.4. Global Biologics and Biosimilars by: Route of administration (Value)
        • 7.2.4.1. Injection
        • 7.2.4.2. Infusion
      • 7.2.5. Global Biologics and Biosimilars Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Biologics and Biosimilars (Volume)
      • 7.3.1. Global Biologics and Biosimilars by: Type (Volume)
        • 7.3.1.1. Monoclonal Antibodies
        • 7.3.1.2. Interferon
        • 7.3.1.3. Erythropoietin
        • 7.3.1.4. Insulin
        • 7.3.1.5. Vaccines
        • 7.3.1.6. Other
      • 7.3.2. Global Biologics and Biosimilars by: Application (Volume)
        • 7.3.2.1. Tumor
        • 7.3.2.2. Diabetes
        • 7.3.2.3. Cardiovascular
        • 7.3.2.4. Hemophilia
        • 7.3.2.5. Other
      • 7.3.3. Global Biologics and Biosimilars by: Disease Type (Volume)
        • 7.3.3.1. Oncology
        • 7.3.3.2. Blood Disorders
        • 7.3.3.3. Chronic Diseases
        • 7.3.3.4. Autoimmune Diseases
        • 7.3.3.5. Growth Hormone Deficiency
        • 7.3.3.6. Infectious Diseases
        • 7.3.3.7. Other Diseases
      • 7.3.4. Global Biologics and Biosimilars by: Route of administration (Volume)
        • 7.3.4.1. Injection
        • 7.3.4.2. Infusion
      • 7.3.5. Global Biologics and Biosimilars Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Biologics and Biosimilars (Price)
      • 7.4.1. Global Biologics and Biosimilars by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biologics and Biosimilars: by Type(USD Million)
  • Table 2. Biologics and Biosimilars Monoclonal Antibodies , by Region USD Million (2016-2021)
  • Table 3. Biologics and Biosimilars Interferon , by Region USD Million (2016-2021)
  • Table 4. Biologics and Biosimilars Erythropoietin , by Region USD Million (2016-2021)
  • Table 5. Biologics and Biosimilars Insulin , by Region USD Million (2016-2021)
  • Table 6. Biologics and Biosimilars Vaccines , by Region USD Million (2016-2021)
  • Table 7. Biologics and Biosimilars Other , by Region USD Million (2016-2021)
  • Table 8. Biologics and Biosimilars: by Application(USD Million)
  • Table 9. Biologics and Biosimilars Tumor , by Region USD Million (2016-2021)
  • Table 10. Biologics and Biosimilars Diabetes , by Region USD Million (2016-2021)
  • Table 11. Biologics and Biosimilars Cardiovascular , by Region USD Million (2016-2021)
  • Table 12. Biologics and Biosimilars Hemophilia , by Region USD Million (2016-2021)
  • Table 13. Biologics and Biosimilars Other , by Region USD Million (2016-2021)
  • Table 14. Biologics and Biosimilars: by Disease Type(USD Million)
  • Table 15. Biologics and Biosimilars Oncology , by Region USD Million (2016-2021)
  • Table 16. Biologics and Biosimilars Blood Disorders , by Region USD Million (2016-2021)
  • Table 17. Biologics and Biosimilars Chronic Diseases , by Region USD Million (2016-2021)
  • Table 18. Biologics and Biosimilars Autoimmune Diseases , by Region USD Million (2016-2021)
  • Table 19. Biologics and Biosimilars Growth Hormone Deficiency , by Region USD Million (2016-2021)
  • Table 20. Biologics and Biosimilars Infectious Diseases , by Region USD Million (2016-2021)
  • Table 21. Biologics and Biosimilars Other Diseases , by Region USD Million (2016-2021)
  • Table 22. Biologics and Biosimilars: by Route of administration(USD Million)
  • Table 23. Biologics and Biosimilars Injection , by Region USD Million (2016-2021)
  • Table 24. Biologics and Biosimilars Infusion , by Region USD Million (2016-2021)
  • Table 25. South America Biologics and Biosimilars, by Country USD Million (2016-2021)
  • Table 26. South America Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 27. South America Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 28. South America Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 29. South America Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 30. Brazil Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 31. Brazil Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 32. Brazil Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 33. Brazil Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 34. Argentina Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 35. Argentina Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 36. Argentina Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 37. Argentina Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 38. Rest of South America Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 39. Rest of South America Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 40. Rest of South America Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 41. Rest of South America Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 42. Asia Pacific Biologics and Biosimilars, by Country USD Million (2016-2021)
  • Table 43. Asia Pacific Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 44. Asia Pacific Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 45. Asia Pacific Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 46. Asia Pacific Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 47. China Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 48. China Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 49. China Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 50. China Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 51. Japan Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 52. Japan Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 53. Japan Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 54. Japan Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 55. India Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 56. India Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 57. India Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 58. India Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 59. South Korea Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 60. South Korea Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 61. South Korea Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 62. South Korea Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 63. Taiwan Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 64. Taiwan Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 65. Taiwan Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 66. Taiwan Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 67. Australia Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 68. Australia Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 69. Australia Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 70. Australia Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 71. Rest of Asia-Pacific Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 72. Rest of Asia-Pacific Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 73. Rest of Asia-Pacific Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 74. Rest of Asia-Pacific Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 75. Europe Biologics and Biosimilars, by Country USD Million (2016-2021)
  • Table 76. Europe Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 77. Europe Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 78. Europe Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 79. Europe Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 80. Germany Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 81. Germany Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 82. Germany Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 83. Germany Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 84. France Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 85. France Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 86. France Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 87. France Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 88. Italy Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 89. Italy Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 90. Italy Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 91. Italy Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 92. United Kingdom Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 93. United Kingdom Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 94. United Kingdom Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 95. United Kingdom Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 96. Netherlands Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 97. Netherlands Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 98. Netherlands Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 99. Netherlands Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 100. Rest of Europe Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 101. Rest of Europe Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 102. Rest of Europe Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 103. Rest of Europe Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 104. MEA Biologics and Biosimilars, by Country USD Million (2016-2021)
  • Table 105. MEA Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 106. MEA Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 107. MEA Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 108. MEA Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 109. Middle East Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 110. Middle East Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 111. Middle East Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 112. Middle East Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 113. Africa Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 114. Africa Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 115. Africa Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 116. Africa Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 117. North America Biologics and Biosimilars, by Country USD Million (2016-2021)
  • Table 118. North America Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 119. North America Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 120. North America Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 121. North America Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 122. United States Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 123. United States Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 124. United States Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 125. United States Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 126. Canada Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 127. Canada Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 128. Canada Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 129. Canada Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 130. Mexico Biologics and Biosimilars, by Type USD Million (2016-2021)
  • Table 131. Mexico Biologics and Biosimilars, by Application USD Million (2016-2021)
  • Table 132. Mexico Biologics and Biosimilars, by Disease Type USD Million (2016-2021)
  • Table 133. Mexico Biologics and Biosimilars, by Route of administration USD Million (2016-2021)
  • Table 134. Biologics and Biosimilars Sales: by Type(unit)
  • Table 135. Biologics and Biosimilars Sales Monoclonal Antibodies , by Region unit (2016-2021)
  • Table 136. Biologics and Biosimilars Sales Interferon , by Region unit (2016-2021)
  • Table 137. Biologics and Biosimilars Sales Erythropoietin , by Region unit (2016-2021)
  • Table 138. Biologics and Biosimilars Sales Insulin , by Region unit (2016-2021)
  • Table 139. Biologics and Biosimilars Sales Vaccines , by Region unit (2016-2021)
  • Table 140. Biologics and Biosimilars Sales Other , by Region unit (2016-2021)
  • Table 141. Biologics and Biosimilars Sales: by Application(unit)
  • Table 142. Biologics and Biosimilars Sales Tumor , by Region unit (2016-2021)
  • Table 143. Biologics and Biosimilars Sales Diabetes , by Region unit (2016-2021)
  • Table 144. Biologics and Biosimilars Sales Cardiovascular , by Region unit (2016-2021)
  • Table 145. Biologics and Biosimilars Sales Hemophilia , by Region unit (2016-2021)
  • Table 146. Biologics and Biosimilars Sales Other , by Region unit (2016-2021)
  • Table 147. Biologics and Biosimilars Sales: by Disease Type(unit)
  • Table 148. Biologics and Biosimilars Sales Oncology , by Region unit (2016-2021)
  • Table 149. Biologics and Biosimilars Sales Blood Disorders , by Region unit (2016-2021)
  • Table 150. Biologics and Biosimilars Sales Chronic Diseases , by Region unit (2016-2021)
  • Table 151. Biologics and Biosimilars Sales Autoimmune Diseases , by Region unit (2016-2021)
  • Table 152. Biologics and Biosimilars Sales Growth Hormone Deficiency , by Region unit (2016-2021)
  • Table 153. Biologics and Biosimilars Sales Infectious Diseases , by Region unit (2016-2021)
  • Table 154. Biologics and Biosimilars Sales Other Diseases , by Region unit (2016-2021)
  • Table 155. Biologics and Biosimilars Sales: by Route of administration(unit)
  • Table 156. Biologics and Biosimilars Sales Injection , by Region unit (2016-2021)
  • Table 157. Biologics and Biosimilars Sales Infusion , by Region unit (2016-2021)
  • Table 158. South America Biologics and Biosimilars Sales, by Country unit (2016-2021)
  • Table 159. South America Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 160. South America Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 161. South America Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 162. South America Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 163. Brazil Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 164. Brazil Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 165. Brazil Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 166. Brazil Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 167. Argentina Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 168. Argentina Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 169. Argentina Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 170. Argentina Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 171. Rest of South America Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 172. Rest of South America Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 173. Rest of South America Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 174. Rest of South America Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 175. Asia Pacific Biologics and Biosimilars Sales, by Country unit (2016-2021)
  • Table 176. Asia Pacific Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 177. Asia Pacific Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 178. Asia Pacific Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 179. Asia Pacific Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 180. China Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 181. China Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 182. China Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 183. China Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 184. Japan Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 185. Japan Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 186. Japan Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 187. Japan Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 188. India Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 189. India Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 190. India Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 191. India Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 192. South Korea Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 193. South Korea Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 194. South Korea Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 195. South Korea Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 196. Taiwan Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 197. Taiwan Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 198. Taiwan Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 199. Taiwan Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 200. Australia Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 201. Australia Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 202. Australia Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 203. Australia Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 204. Rest of Asia-Pacific Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 205. Rest of Asia-Pacific Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 206. Rest of Asia-Pacific Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 207. Rest of Asia-Pacific Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 208. Europe Biologics and Biosimilars Sales, by Country unit (2016-2021)
  • Table 209. Europe Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 210. Europe Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 211. Europe Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 212. Europe Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 213. Germany Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 214. Germany Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 215. Germany Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 216. Germany Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 217. France Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 218. France Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 219. France Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 220. France Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 221. Italy Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 222. Italy Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 223. Italy Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 224. Italy Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 225. United Kingdom Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 226. United Kingdom Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 227. United Kingdom Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 228. United Kingdom Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 229. Netherlands Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 230. Netherlands Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 231. Netherlands Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 232. Netherlands Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 233. Rest of Europe Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 234. Rest of Europe Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 235. Rest of Europe Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 236. Rest of Europe Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 237. MEA Biologics and Biosimilars Sales, by Country unit (2016-2021)
  • Table 238. MEA Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 239. MEA Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 240. MEA Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 241. MEA Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 242. Middle East Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 243. Middle East Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 244. Middle East Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 245. Middle East Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 246. Africa Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 247. Africa Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 248. Africa Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 249. Africa Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 250. North America Biologics and Biosimilars Sales, by Country unit (2016-2021)
  • Table 251. North America Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 252. North America Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 253. North America Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 254. North America Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 255. United States Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 256. United States Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 257. United States Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 258. United States Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 259. Canada Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 260. Canada Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 261. Canada Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 262. Canada Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 263. Mexico Biologics and Biosimilars Sales, by Type unit (2016-2021)
  • Table 264. Mexico Biologics and Biosimilars Sales, by Application unit (2016-2021)
  • Table 265. Mexico Biologics and Biosimilars Sales, by Disease Type unit (2016-2021)
  • Table 266. Mexico Biologics and Biosimilars Sales, by Route of administration unit (2016-2021)
  • Table 267. Biologics and Biosimilars: by Type(USD/Units)
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Company Basic Information, Sales Area and Its Competitors
  • Table 276. Company Basic Information, Sales Area and Its Competitors
  • Table 277. Company Basic Information, Sales Area and Its Competitors
  • Table 278. Biologics and Biosimilars: by Type(USD Million)
  • Table 279. Biologics and Biosimilars Monoclonal Antibodies , by Region USD Million (2022-2027)
  • Table 280. Biologics and Biosimilars Interferon , by Region USD Million (2022-2027)
  • Table 281. Biologics and Biosimilars Erythropoietin , by Region USD Million (2022-2027)
  • Table 282. Biologics and Biosimilars Insulin , by Region USD Million (2022-2027)
  • Table 283. Biologics and Biosimilars Vaccines , by Region USD Million (2022-2027)
  • Table 284. Biologics and Biosimilars Other , by Region USD Million (2022-2027)
  • Table 285. Biologics and Biosimilars: by Application(USD Million)
  • Table 286. Biologics and Biosimilars Tumor , by Region USD Million (2022-2027)
  • Table 287. Biologics and Biosimilars Diabetes , by Region USD Million (2022-2027)
  • Table 288. Biologics and Biosimilars Cardiovascular , by Region USD Million (2022-2027)
  • Table 289. Biologics and Biosimilars Hemophilia , by Region USD Million (2022-2027)
  • Table 290. Biologics and Biosimilars Other , by Region USD Million (2022-2027)
  • Table 291. Biologics and Biosimilars: by Disease Type(USD Million)
  • Table 292. Biologics and Biosimilars Oncology , by Region USD Million (2022-2027)
  • Table 293. Biologics and Biosimilars Blood Disorders , by Region USD Million (2022-2027)
  • Table 294. Biologics and Biosimilars Chronic Diseases , by Region USD Million (2022-2027)
  • Table 295. Biologics and Biosimilars Autoimmune Diseases , by Region USD Million (2022-2027)
  • Table 296. Biologics and Biosimilars Growth Hormone Deficiency , by Region USD Million (2022-2027)
  • Table 297. Biologics and Biosimilars Infectious Diseases , by Region USD Million (2022-2027)
  • Table 298. Biologics and Biosimilars Other Diseases , by Region USD Million (2022-2027)
  • Table 299. Biologics and Biosimilars: by Route of administration(USD Million)
  • Table 300. Biologics and Biosimilars Injection , by Region USD Million (2022-2027)
  • Table 301. Biologics and Biosimilars Infusion , by Region USD Million (2022-2027)
  • Table 302. South America Biologics and Biosimilars, by Country USD Million (2022-2027)
  • Table 303. South America Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 304. South America Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 305. South America Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 306. South America Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 307. Brazil Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 308. Brazil Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 309. Brazil Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 310. Brazil Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 311. Argentina Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 312. Argentina Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 313. Argentina Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 314. Argentina Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 315. Rest of South America Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 316. Rest of South America Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 317. Rest of South America Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 318. Rest of South America Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 319. Asia Pacific Biologics and Biosimilars, by Country USD Million (2022-2027)
  • Table 320. Asia Pacific Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 321. Asia Pacific Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 322. Asia Pacific Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 323. Asia Pacific Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 324. China Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 325. China Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 326. China Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 327. China Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 328. Japan Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 329. Japan Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 330. Japan Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 331. Japan Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 332. India Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 333. India Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 334. India Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 335. India Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 336. South Korea Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 337. South Korea Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 338. South Korea Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 339. South Korea Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 340. Taiwan Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 341. Taiwan Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 342. Taiwan Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 343. Taiwan Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 344. Australia Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 345. Australia Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 346. Australia Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 347. Australia Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 348. Rest of Asia-Pacific Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 349. Rest of Asia-Pacific Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 350. Rest of Asia-Pacific Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 351. Rest of Asia-Pacific Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 352. Europe Biologics and Biosimilars, by Country USD Million (2022-2027)
  • Table 353. Europe Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 354. Europe Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 355. Europe Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 356. Europe Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 357. Germany Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 358. Germany Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 359. Germany Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 360. Germany Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 361. France Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 362. France Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 363. France Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 364. France Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 365. Italy Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 366. Italy Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 367. Italy Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 368. Italy Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 369. United Kingdom Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 370. United Kingdom Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 371. United Kingdom Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 372. United Kingdom Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 373. Netherlands Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 374. Netherlands Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 375. Netherlands Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 376. Netherlands Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 377. Rest of Europe Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 378. Rest of Europe Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 379. Rest of Europe Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 380. Rest of Europe Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 381. MEA Biologics and Biosimilars, by Country USD Million (2022-2027)
  • Table 382. MEA Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 383. MEA Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 384. MEA Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 385. MEA Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 386. Middle East Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 387. Middle East Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 388. Middle East Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 389. Middle East Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 390. Africa Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 391. Africa Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 392. Africa Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 393. Africa Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 394. North America Biologics and Biosimilars, by Country USD Million (2022-2027)
  • Table 395. North America Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 396. North America Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 397. North America Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 398. North America Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 399. United States Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 400. United States Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 401. United States Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 402. United States Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 403. Canada Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 404. Canada Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 405. Canada Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 406. Canada Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 407. Mexico Biologics and Biosimilars, by Type USD Million (2022-2027)
  • Table 408. Mexico Biologics and Biosimilars, by Application USD Million (2022-2027)
  • Table 409. Mexico Biologics and Biosimilars, by Disease Type USD Million (2022-2027)
  • Table 410. Mexico Biologics and Biosimilars, by Route of administration USD Million (2022-2027)
  • Table 411. Biologics and Biosimilars Sales: by Type(unit)
  • Table 412. Biologics and Biosimilars Sales Monoclonal Antibodies , by Region unit (2022-2027)
  • Table 413. Biologics and Biosimilars Sales Interferon , by Region unit (2022-2027)
  • Table 414. Biologics and Biosimilars Sales Erythropoietin , by Region unit (2022-2027)
  • Table 415. Biologics and Biosimilars Sales Insulin , by Region unit (2022-2027)
  • Table 416. Biologics and Biosimilars Sales Vaccines , by Region unit (2022-2027)
  • Table 417. Biologics and Biosimilars Sales Other , by Region unit (2022-2027)
  • Table 418. Biologics and Biosimilars Sales: by Application(unit)
  • Table 419. Biologics and Biosimilars Sales Tumor , by Region unit (2022-2027)
  • Table 420. Biologics and Biosimilars Sales Diabetes , by Region unit (2022-2027)
  • Table 421. Biologics and Biosimilars Sales Cardiovascular , by Region unit (2022-2027)
  • Table 422. Biologics and Biosimilars Sales Hemophilia , by Region unit (2022-2027)
  • Table 423. Biologics and Biosimilars Sales Other , by Region unit (2022-2027)
  • Table 424. Biologics and Biosimilars Sales: by Disease Type(unit)
  • Table 425. Biologics and Biosimilars Sales Oncology , by Region unit (2022-2027)
  • Table 426. Biologics and Biosimilars Sales Blood Disorders , by Region unit (2022-2027)
  • Table 427. Biologics and Biosimilars Sales Chronic Diseases , by Region unit (2022-2027)
  • Table 428. Biologics and Biosimilars Sales Autoimmune Diseases , by Region unit (2022-2027)
  • Table 429. Biologics and Biosimilars Sales Growth Hormone Deficiency , by Region unit (2022-2027)
  • Table 430. Biologics and Biosimilars Sales Infectious Diseases , by Region unit (2022-2027)
  • Table 431. Biologics and Biosimilars Sales Other Diseases , by Region unit (2022-2027)
  • Table 432. Biologics and Biosimilars Sales: by Route of administration(unit)
  • Table 433. Biologics and Biosimilars Sales Injection , by Region unit (2022-2027)
  • Table 434. Biologics and Biosimilars Sales Infusion , by Region unit (2022-2027)
  • Table 435. South America Biologics and Biosimilars Sales, by Country unit (2022-2027)
  • Table 436. South America Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 437. South America Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 438. South America Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 439. South America Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 440. Brazil Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 441. Brazil Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 442. Brazil Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 443. Brazil Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 444. Argentina Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 445. Argentina Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 446. Argentina Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 447. Argentina Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 448. Rest of South America Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 449. Rest of South America Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 450. Rest of South America Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 451. Rest of South America Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 452. Asia Pacific Biologics and Biosimilars Sales, by Country unit (2022-2027)
  • Table 453. Asia Pacific Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 454. Asia Pacific Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 455. Asia Pacific Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 456. Asia Pacific Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 457. China Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 458. China Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 459. China Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 460. China Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 461. Japan Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 462. Japan Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 463. Japan Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 464. Japan Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 465. India Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 466. India Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 467. India Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 468. India Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 469. South Korea Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 470. South Korea Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 471. South Korea Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 472. South Korea Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 473. Taiwan Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 474. Taiwan Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 475. Taiwan Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 476. Taiwan Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 477. Australia Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 478. Australia Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 479. Australia Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 480. Australia Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 481. Rest of Asia-Pacific Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 482. Rest of Asia-Pacific Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 483. Rest of Asia-Pacific Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 484. Rest of Asia-Pacific Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 485. Europe Biologics and Biosimilars Sales, by Country unit (2022-2027)
  • Table 486. Europe Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 487. Europe Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 488. Europe Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 489. Europe Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 490. Germany Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 491. Germany Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 492. Germany Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 493. Germany Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 494. France Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 495. France Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 496. France Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 497. France Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 498. Italy Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 499. Italy Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 500. Italy Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 501. Italy Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 502. United Kingdom Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 503. United Kingdom Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 504. United Kingdom Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 505. United Kingdom Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 506. Netherlands Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 507. Netherlands Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 508. Netherlands Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 509. Netherlands Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 510. Rest of Europe Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 511. Rest of Europe Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 512. Rest of Europe Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 513. Rest of Europe Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 514. MEA Biologics and Biosimilars Sales, by Country unit (2022-2027)
  • Table 515. MEA Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 516. MEA Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 517. MEA Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 518. MEA Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 519. Middle East Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 520. Middle East Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 521. Middle East Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 522. Middle East Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 523. Africa Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 524. Africa Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 525. Africa Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 526. Africa Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 527. North America Biologics and Biosimilars Sales, by Country unit (2022-2027)
  • Table 528. North America Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 529. North America Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 530. North America Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 531. North America Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 532. United States Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 533. United States Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 534. United States Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 535. United States Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 536. Canada Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 537. Canada Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 538. Canada Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 539. Canada Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 540. Mexico Biologics and Biosimilars Sales, by Type unit (2022-2027)
  • Table 541. Mexico Biologics and Biosimilars Sales, by Application unit (2022-2027)
  • Table 542. Mexico Biologics and Biosimilars Sales, by Disease Type unit (2022-2027)
  • Table 543. Mexico Biologics and Biosimilars Sales, by Route of administration unit (2022-2027)
  • Table 544. Biologics and Biosimilars: by Type(USD/Units)
  • Table 545. Research Programs/Design for This Report
  • Table 546. Key Data Information from Secondary Sources
  • Table 547. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biologics and Biosimilars: by Type USD Million (2016-2021)
  • Figure 5. Global Biologics and Biosimilars: by Application USD Million (2016-2021)
  • Figure 6. Global Biologics and Biosimilars: by Disease Type USD Million (2016-2021)
  • Figure 7. Global Biologics and Biosimilars: by Route of administration USD Million (2016-2021)
  • Figure 8. South America Biologics and Biosimilars Share (%), by Country
  • Figure 9. Asia Pacific Biologics and Biosimilars Share (%), by Country
  • Figure 10. Europe Biologics and Biosimilars Share (%), by Country
  • Figure 11. MEA Biologics and Biosimilars Share (%), by Country
  • Figure 12. North America Biologics and Biosimilars Share (%), by Country
  • Figure 13. Global Biologics and Biosimilars: by Type unit (2016-2021)
  • Figure 14. Global Biologics and Biosimilars: by Application unit (2016-2021)
  • Figure 15. Global Biologics and Biosimilars: by Disease Type unit (2016-2021)
  • Figure 16. Global Biologics and Biosimilars: by Route of administration unit (2016-2021)
  • Figure 17. South America Biologics and Biosimilars Share (%), by Country
  • Figure 18. Asia Pacific Biologics and Biosimilars Share (%), by Country
  • Figure 19. Europe Biologics and Biosimilars Share (%), by Country
  • Figure 20. MEA Biologics and Biosimilars Share (%), by Country
  • Figure 21. North America Biologics and Biosimilars Share (%), by Country
  • Figure 22. Global Biologics and Biosimilars: by Type USD/Units (2016-2021)
  • Figure 23. Global Biologics and Biosimilars share by Players 2021 (%)
  • Figure 24. Global Biologics and Biosimilars share by Players (Top 3) 2021(%)
  • Figure 25. Global Biologics and Biosimilars share by Players (Top 5) 2021(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche (Switzerland) Revenue: by Geography 2021
  • Figure 29. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 30. Amgen (United States) Revenue: by Geography 2021
  • Figure 31. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 32. AbbVie (United States) Revenue: by Geography 2021
  • Figure 33. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi-Aventis (France) Revenue: by Geography 2021
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 37. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer (United States) Revenue: by Geography 2021
  • Figure 39. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 40. Novo Nordisk (Denmark) Revenue: by Geography 2021
  • Figure 41. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 42. Eli Lilly (United States) Revenue: by Geography 2021
  • Figure 43. Novartis (United States) Revenue, Net Income and Gross profit
  • Figure 44. Novartis (United States) Revenue: by Geography 2021
  • Figure 45. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 46. Merck (United States) Revenue: by Geography 2021
  • Figure 47. Global Biologics and Biosimilars: by Type USD Million (2022-2027)
  • Figure 48. Global Biologics and Biosimilars: by Application USD Million (2022-2027)
  • Figure 49. Global Biologics and Biosimilars: by Disease Type USD Million (2022-2027)
  • Figure 50. Global Biologics and Biosimilars: by Route of administration USD Million (2022-2027)
  • Figure 51. South America Biologics and Biosimilars Share (%), by Country
  • Figure 52. Asia Pacific Biologics and Biosimilars Share (%), by Country
  • Figure 53. Europe Biologics and Biosimilars Share (%), by Country
  • Figure 54. MEA Biologics and Biosimilars Share (%), by Country
  • Figure 55. North America Biologics and Biosimilars Share (%), by Country
  • Figure 56. Global Biologics and Biosimilars: by Type unit (2022-2027)
  • Figure 57. Global Biologics and Biosimilars: by Application unit (2022-2027)
  • Figure 58. Global Biologics and Biosimilars: by Disease Type unit (2022-2027)
  • Figure 59. Global Biologics and Biosimilars: by Route of administration unit (2022-2027)
  • Figure 60. South America Biologics and Biosimilars Share (%), by Country
  • Figure 61. Asia Pacific Biologics and Biosimilars Share (%), by Country
  • Figure 62. Europe Biologics and Biosimilars Share (%), by Country
  • Figure 63. MEA Biologics and Biosimilars Share (%), by Country
  • Figure 64. North America Biologics and Biosimilars Share (%), by Country
  • Figure 65. Global Biologics and Biosimilars: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Roche (Switzerland)
  • Amgen (United States)
  • AbbVie (United States)
  • Sanofi-Aventis (France)
  • Johnson & Johnson (United States)
  • Pfizer (United States)
  • Novo Nordisk (Denmark)
  • Eli Lilly (United States)
  • Novartis (United States)
  • Merck (United States)
Additional players considered in the study are as follows:
3sbio (China) , Changchun High Tech (China) , Ganlee (China)
Select User Access Type

Key Highlights of Report


May 2022 239 Pages 66 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biologics and Biosimilars Quantitative research analysis
Global Biologics and Biosimilars Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Biologics and Biosimilars market are Roche (Switzerland), Amgen (United States), AbbVie (United States), Sanofi-Aventis (France), Johnson & Johnson (United States), Pfizer (United States), Novo Nordisk (Denmark), Eli Lilly (United States), Novartis (United States) and Merck (United States), to name a few.
"The Increasing Rate of Patients and Physicians Willingness to Switch to Biosimilar " is seen as one of major influencing trends for Biologics and Biosimilars Market during projected period 2021-2027.

Know More About Global Biologics and Biosimilars Report?

Have a Query? Click Here

Other Related Reports

Test Tubes Comprehensive Study by Type (Disposable, Reusable), Application (Chemistry, Biosciences, Medical, Other), Capacity (3 ml, 5 ml, 9 ml, 14 ml, Others), Sales Channel (Online, Offline), Mater...
$ 3350
Life Science Tool Comprehensive Study by Type (Detection Probes , Light Microscopy , Confocal Microscopy , Electron Microscopy , Others ), Application (DNA Research , RNA Research , Proteomics , Prot...
$ 3350
Compound Optical Microscope Comprehensive Study by Type (Comparison Microscope, Inverted Microscope, Phase Contrast Microscope, Polarizing Microscope, Fluorescence Microscope, Others), Application (H...
$ 3750
Life Science Analytics Comprehensive Study by Type (Descriptive Analysis, Predictive Analysis, Prescriptive Analysis, Reporting Analysis), Application (Biotech Companies, Medical Equipment Enterprise...
$ 3750
Cath Lab Services Comprehensive Study by Type (Vascular Angiogram, Vascular Angioplasty and Stenting, Cardiac Catherization, Carotid Artery Stenting), Application (Hospital, Clinic, Others), Services...
$ 3650
Test Management Tools Comprehensive Study by Application (Data subsetting, Data masking, Data profiling and analysis, Data compliance and security, Synthetic test data generation, Others), Vertical (...
$ 3750